Drug Profile

AD 209

Alternative Names: AD-209

Latest Information Update: 05 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Addpharma
Class Antihypertensives
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase III Essential hypertension

Most Recent Events

19 Sep 2024 Efficacy and adverse events data from a phase II trial in Essential hypertension presented at the the International Society of Hypertension (ISH-2024)
20 May 2024 Phase-III clinical trials in Essential hypertension in South Korea (PO) (NCT06348576)
04 Apr 2024 Addpharma plans phase-III trial for Essential hypertension in South Korea (PO) in April 2024 , (NCT06348576)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com